First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study

Abstract Background and Aims Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first‐line therapy and to investigate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shigeo Shimose, Atsushi Hiraoka, Masahito Nakano, Hideki Iwamoto, Masatoshi Tanaka, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Kei Ogata, Masahiko Kajiwara, Satoshi Itano, Yoshinori Yokokura, Taizo Yamaguchi, Hiroshi Kawano, Norito Matsukuma, Hideya Suga, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Takumi Kawaguchi, Hironori Koga, Takuji Torimura
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	carcinoma hepatocellular nonalcoholic steatohepatitis sequential therapy sorafenib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0894e9642c0c4631b38c4aa5d3985b9c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0894e9642c0c4631b38c4aa5d3985b9c
record_format	dspace
spelling	oai:doaj.org-article:0894e9642c0c4631b38c4aa5d3985b9c2021-12-01T04:49:16ZFirst‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study2045-763410.1002/cam4.4367https://doaj.org/article/0894e9642c0c4631b38c4aa5d3985b9c2021-12-01T00:00:00Zhttps://doi.org/10.1002/cam4.4367https://doaj.org/toc/2045-7634Abstract Background and Aims Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first‐line therapy and to investigate the therapeutic impact of SORA in nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steato hepatitis (NASH)‐related HCC. Methods We evaluated 504 HCC patients treated with SORA (Study‐1). The times of administration for sorafenib from 2009 to 2015, 2016 to 2017, and 2018 and later were defined as the early‐, mid‐, and late‐term periods, respectively. Among them, 180 HCC patients treated with SORA in addition to MTAs in the mid‐ and late‐term periods were divided into groups based on disease etiology (NAFLD or NASH [n = 37] and viral or alcohol [n = 143]), and outcomes were compared after inverse probability weighting (IPW) (Study‐2). Results Overall survival (OS) of HCC patients who received sequential MTA therapy after first‐line SORA was significantly longer. The median survival times (MST) were 12.6 versus 17.6 versus 17.4 months in the early‐term group, mid‐term group, and the later‐time group (early vs. mid, p = 0.014, early vs. later. p = 0.045), respectively. (Study‐1). In Study‐2, there was no significant differences in OS between the Virus/alcohol group and the NAFLD/NASH group in patients who received sequential therapy (MST was 23.4 and 27.0 months p = 0.173, respectively). The NAFLD or NASH, female sex, albumin‐bilirubin (ALBI) grade 2b, and major Vp (Vp3/Vp4) were significant factors for OS treated with SORA. Conclusions Sequential therapy with SORA as the first‐line treatment improved the prognosis of unresectable HCC patients and was effective regardless of HCC etiology.Shigeo ShimoseAtsushi HiraokaMasahito NakanoHideki IwamotoMasatoshi TanakaTakaaki TanakaKazunori NoguchiHajime AinoKei OgataMasahiko KajiwaraSatoshi ItanoYoshinori YokokuraTaizo YamaguchiHiroshi KawanoNorito MatsukumaHideya SugaTakashi NiizekiTomotake ShironoYu NodaNaoki KamachiShusuke OkamuraTakumi KawaguchiHironori KogaTakuji TorimuraWileyarticlecarcinomahepatocellularnonalcoholic steatohepatitissequential therapysorafenibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 23, Pp 8530-8541 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	carcinoma hepatocellular nonalcoholic steatohepatitis sequential therapy sorafenib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	carcinoma hepatocellular nonalcoholic steatohepatitis sequential therapy sorafenib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Shigeo Shimose Atsushi Hiraoka Masahito Nakano Hideki Iwamoto Masatoshi Tanaka Takaaki Tanaka Kazunori Noguchi Hajime Aino Kei Ogata Masahiko Kajiwara Satoshi Itano Yoshinori Yokokura Taizo Yamaguchi Hiroshi Kawano Norito Matsukuma Hideya Suga Takashi Niizeki Tomotake Shirono Yu Noda Naoki Kamachi Shusuke Okamura Takumi Kawaguchi Hironori Koga Takuji Torimura First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
description	Abstract Background and Aims Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first‐line therapy and to investigate the therapeutic impact of SORA in nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steato hepatitis (NASH)‐related HCC. Methods We evaluated 504 HCC patients treated with SORA (Study‐1). The times of administration for sorafenib from 2009 to 2015, 2016 to 2017, and 2018 and later were defined as the early‐, mid‐, and late‐term periods, respectively. Among them, 180 HCC patients treated with SORA in addition to MTAs in the mid‐ and late‐term periods were divided into groups based on disease etiology (NAFLD or NASH [n = 37] and viral or alcohol [n = 143]), and outcomes were compared after inverse probability weighting (IPW) (Study‐2). Results Overall survival (OS) of HCC patients who received sequential MTA therapy after first‐line SORA was significantly longer. The median survival times (MST) were 12.6 versus 17.6 versus 17.4 months in the early‐term group, mid‐term group, and the later‐time group (early vs. mid, p = 0.014, early vs. later. p = 0.045), respectively. (Study‐1). In Study‐2, there was no significant differences in OS between the Virus/alcohol group and the NAFLD/NASH group in patients who received sequential therapy (MST was 23.4 and 27.0 months p = 0.173, respectively). The NAFLD or NASH, female sex, albumin‐bilirubin (ALBI) grade 2b, and major Vp (Vp3/Vp4) were significant factors for OS treated with SORA. Conclusions Sequential therapy with SORA as the first‐line treatment improved the prognosis of unresectable HCC patients and was effective regardless of HCC etiology.
format	article
author	Shigeo Shimose Atsushi Hiraoka Masahito Nakano Hideki Iwamoto Masatoshi Tanaka Takaaki Tanaka Kazunori Noguchi Hajime Aino Kei Ogata Masahiko Kajiwara Satoshi Itano Yoshinori Yokokura Taizo Yamaguchi Hiroshi Kawano Norito Matsukuma Hideya Suga Takashi Niizeki Tomotake Shirono Yu Noda Naoki Kamachi Shusuke Okamura Takumi Kawaguchi Hironori Koga Takuji Torimura
author_facet	Shigeo Shimose Atsushi Hiraoka Masahito Nakano Hideki Iwamoto Masatoshi Tanaka Takaaki Tanaka Kazunori Noguchi Hajime Aino Kei Ogata Masahiko Kajiwara Satoshi Itano Yoshinori Yokokura Taizo Yamaguchi Hiroshi Kawano Norito Matsukuma Hideya Suga Takashi Niizeki Tomotake Shirono Yu Noda Naoki Kamachi Shusuke Okamura Takumi Kawaguchi Hironori Koga Takuji Torimura
author_sort	Shigeo Shimose
title	First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
title_short	First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
title_full	First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
title_fullStr	First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
title_full_unstemmed	First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
title_sort	first‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: a multicenter retrospective study
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/0894e9642c0c4631b38c4aa5d3985b9c
work_keys_str_mv	AT shigeoshimose firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT atsushihiraoka firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT masahitonakano firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT hidekiiwamoto firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT masatoshitanaka firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT takaakitanaka firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT kazunorinoguchi firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT hajimeaino firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT keiogata firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT masahikokajiwara firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT satoshiitano firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT yoshinoriyokokura firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT taizoyamaguchi firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT hiroshikawano firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT noritomatsukuma firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT hideyasuga firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT takashiniizeki firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT tomotakeshirono firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT yunoda firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT naokikamachi firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT shusukeokamura firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT takumikawaguchi firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT hironorikoga firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT takujitorimura firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy
_version_	1718405706386767872

First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study

Ejemplares similares